Table of contents

- MM Overview
- BMS MM Portfolio
- MM Product Module
- Patient Access Support
- Summary

Abbreviation: MM, multiple myeloma.
Multiple myeloma: A rare,* incurable hematologic cancer\(^{1,2}\)


Almost all patients will experience relapse, and/or the disease will become refractory\(^2\)

* Affects fewer than 200,000 people in the United States.\(^1\)
Patients with MM typically experience multiple periods of response, remission, and relapse\(^1\)

Abbreviation: MM, multiple myeloma.

---

The natural course of disease highlights the necessity for durable treatments to delay progression and sustain remission.

---

Natural history of MM\(^1\)


This work is an open-access publication originally published by IntechOpen as an OA (open-access).
Prevalence of multiple myeloma (MM) by line of therapy\(^1-3\)

Total number of patients with MM in each line of therapy per 100,000 people (N = 59)\(^a\)

Distribution by line of therapy

1L THERAPY: 34/59 PATIENTS
2L THERAPY: 15/59 PATIENTS
3L THERAPY: 7/59 PATIENTS
4L+ THERAPY: 3/59 PATIENTS

\(^a\)Based on a BMS analysis of LoT distribution from Putnam applied to 2018 SEER prevalence of MM (~150,000) and estimated US adult population.

Abbreviations: 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line; LoT, line of therapy; SEER, Surveillance, Epidemiology, and End Results.

References

1. Data on file, Bristol-Myers Squibb Co.
There has been a substantial improvement over time in long-term outcomes among patients with MM.

Despite advancements, SEER reports that almost half of patients are not expected to survive 5 years from MM diagnosis.

References

*Historical median OS for patients with MM based on analysis of the National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) (1990-2008).
*Predictive analysis of OS (2008 and beyond) was modeled using data from clinical trials, cancer registries, and insights from key opinion leaders.
Abbreviations: mAb, monoclonal antibody; MM, multiple myeloma; OS, overall survival; PI, proteasome inhibitor; SCT, stem cell transplantation.
BMS is committed to the treatment of multiple myeloma (MM) through continued innovation

1. Data on file, Bristol-Myers Squibb Co.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 15, 2022. To view the most recent and complete version of the guidelines, go online to NCCN.org.
3. REVLIMID. Package insert. Celgene Corp.
4. POMALYST. Package insert. Celgene Corp.
5. EMPLICITI. Package insert. Bristol-Myers Squibb Co.
6. ABECMA. Package insert. Celgene Corp.

Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.

SELECTED IMPORTANT SAFETY INFORMATION FOR EMPLICITI: WARNINGS AND PRECAUTIONS (cont’d)

Infections
- In the ELOQUENT-3 trial (N=115), infections were reported in 65% of patients in both the EPd arm and the Pd arm. Grade 3 to 4 infections were reported in 13% (EPd) and 22% (Pd). Discontinuations due to infections were 7% (EPd) and 5% (Pd). Fatal infections were 5% (EPd) and 3.6% (Pd). Opportunistic infections were reported in 10% (EPd) and 9% (Pd). Herpes zoster was reported in 5% (EPd) and 1.8% (Pd).
- Monitor patients for development of infections and treat promptly.

Please see additional REVLIMID, POMALYST, and ABECMA Important Safety Information and full Prescribing Information, including Boxed WARNINGS, at links below. Please see additional EMPLICITI Important Safety Information and full Prescribing Information at links below.
INDICATIONS

REVLIMID, in combination with dexamethasone, is indicated for adult patients who are newly diagnosed and not eligible for a transplant.

REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

POMALYST, in combination with dexamethasone, is indicated for patients with relapsed multiple myeloma who have received at least two prior therapies, including REVLIMID and a PI.

EMPLICITI, in combination with POMALYST and dexamethasone, is indicated for patients with relapsed multiple myeloma who have received at least two prior therapies, including REVLIMID and a PI.

References

1. REVLIMID. Package insert. Celgene Corp.
3. POMALYST. Package insert. Celgene Corp.
5. ABECMA. Package insert. Celgene Corp.
Thank you